Roundview Capital LLC Continues to Hold Position in Abbott Laboratories (ABT)

Roundview Capital LLC continued to hold its stake in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,195 shares of the healthcare product maker’s stock at the end of the fourth quarter. Roundview Capital LLC’s holdings in Abbott Laboratories were worth $238,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Patten Group Inc. increased its position in Abbott Laboratories by 66.0% in the third quarter. Patten Group Inc. now owns 2,516 shares of the healthcare product maker’s stock worth $103,000 after buying an additional 1,000 shares in the last quarter. Kanaly Trust Co increased its position in Abbott Laboratories by 3.7% in the third quarter. Kanaly Trust Co now owns 2,584 shares of the healthcare product maker’s stock worth $109,000 after buying an additional 91 shares in the last quarter. Guidant Wealth Advisors bought a new position in Abbott Laboratories during the third quarter worth $130,000. Bruderman Asset Management LLC increased its position in Abbott Laboratories by 0.3% in the third quarter. Bruderman Asset Management LLC now owns 3,124 shares of the healthcare product maker’s stock worth $132,000 after buying an additional 10 shares in the last quarter. Finally, Apriem Advisors increased its position in Abbott Laboratories by 4.2% in the third quarter. Apriem Advisors now owns 3,419 shares of the healthcare product maker’s stock worth $145,000 after buying an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 62.20% of the company’s stock.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT) opened at 44.98 on Tuesday. Abbott Laboratories has a 12-month low of $36.76 and a 12-month high of $45.84. The stock’s 50 day moving average price is $44.15 and its 200-day moving average price is $41.25. The firm has a market cap of $77.73 billion, a PE ratio of 48.00 and a beta of 0.97.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Monday, February 6th. The healthcare product maker reported $0.65 earnings per share for the quarter, meeting the consensus estimate of $0.65. Abbott Laboratories had a return on equity of 15.74% and a net margin of 6.71%. The business earned $5.33 billion during the quarter, compared to analyst estimates of $5.41 billion. During the same period in the prior year, the company earned $0.62 earnings per share. Abbott Laboratories’s revenue was up 2.8% compared to the same quarter last year. Equities research analysts anticipate that Abbott Laboratories will post $2.45 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, May 15th. Shareholders of record on Friday, April 14th will be issued a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a yield of 2.36%. The ex-dividend date is Tuesday, April 11th. Abbott Laboratories’s dividend payout ratio (DPR) is 113.98%.

var userip;Your IP Address: document.write(userip);

A number of research analysts have weighed in on the company. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Wednesday, March 8th. BMO Capital Markets downgraded Abbott Laboratories from an “outperform” rating to a “market perform” rating and set a $48.00 target price for the company. in a research note on Tuesday, March 14th. Jefferies Group LLC lifted their target price on Abbott Laboratories from $47.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, January 20th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th. Finally, Royal Bank of Canada lifted their target price on Abbott Laboratories from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 1st. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Abbott Laboratories has a consensus rating of “Buy” and a consensus price target of $48.27.

In other news, insider Roger Bird sold 13,222 shares of the firm’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $45.02, for a total value of $595,254.44. Following the completion of the transaction, the insider now directly owns 63,910 shares of the company’s stock, valued at $2,877,228.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Heather L. Mason sold 35,700 shares of the firm’s stock in a transaction on Tuesday, January 31st. The stock was sold at an average price of $40.77, for a total value of $1,455,489.00. Following the completion of the transaction, the insider now directly owns 100,189 shares of the company’s stock, valued at $4,084,705.53. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,592 shares of company stock valued at $3,400,139. 0.26% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

5 Day Chart for NYSE:ABT

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Barclays Comes Up Short, Shares Fall
Barclays Comes Up Short, Shares Fall
Revenue at Twitter Beats the Street, Monthly Users Increase
Revenue at Twitter Beats the Street, Monthly Users Increase
McDonald’s Ordering Via Mobile Could Give Handsome Return
McDonald’s Ordering Via Mobile Could Give Handsome Return
Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor


© 2006-2017 Ticker Report. Google+.